

## ICMJE DISCLOSURE FORM

Date: March 18<sup>th</sup>, 2022  
 Your Name: Yinning Xu  
 Manuscript Title: Heterogeneous microenvironment analysis to explore the potential regulatory role of endothelial-mesenchymal transition in idiopathic pulmonary fibrosis.  
 Manuscript number (if known): \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the **current manuscript only**.

The author’s relationships/activities/interests should be **defined broadly**. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<b>Funding:</b> This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of	



8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

**Please summarize the above conflict of interest in the following box:**

This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of Zhejiang Province (No. 2018ZZ006, 2020ZZ003, 2021ZQ012, 2021ZA006, 2021ZQ012, and 2022ZZ001), the “10000 Talents Plan” of Zhejiang Province to Ping Huang (No. 2020R52029), the National Natural Science Foundation of China and the Swedish Research Council Cooperative Research Project (No. 8211101233), the National Natural Science Foundation of China (No. 8217131437), and the Zhejiang Provincial Science and Technology Department’s “top soldier” and “leading wild goose” R & D project (No. 2022C03116).

**Please place an “X” next to the following statement to indicate your agreement:**

X **I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

Date: March 18<sup>th</sup>, 2022  
 Your Name: Xiaoping Hu  
 Manuscript Title: Heterogeneous microenvironment analysis to explore the potential regulatory role of endothelial-mesenchymal transition in idiopathic pulmonary fibrosis.  
 Manuscript number (if known): \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the **current manuscript only**.

The author's relationships/activities/interests should be **defined broadly**. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<b>Funding:</b> This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of	



8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

**Please summarize the above conflict of interest in the following box:**

This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of Zhejiang Province (No. 2018ZZ006, 2020ZZ003, 2021ZQ012, 2021ZA006, 2021ZQ012, and 2022ZZ001), the “10000 Talents Plan” of Zhejiang Province to Ping Huang (No. 2020R52029), the National Natural Science Foundation of China and the Swedish Research Council Cooperative Research Project (No. 8211101233), the National Natural Science Foundation of China (No. 8217131437), and the Zhejiang Provincial Science and Technology Department’s “top soldier” and “leading wild goose” R & D project (No. 2022C03116).

**Please place an “X” next to the following statement to indicate your agreement:**

X **I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

Date: March 18<sup>th</sup>, 2022  
 Your Name: Yiwen Zhang  
 Manuscript Title: Heterogeneous microenvironment analysis to explore the potential regulatory role of endothelial-mesenchymal transition in idiopathic pulmonary fibrosis.  
 Manuscript number (if known): \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the **current manuscript only**.

The author’s relationships/activities/interests should be **defined broadly**. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<b>Funding:</b> This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of	

		Zhejiang Province (No. 2018ZZ006, 2020ZZ003, 2021ZQ012, 2021ZA006, 2021ZQ012, and 2022ZZ001), the “10000 Talents Plan” of Zhejiang Province to Ping Huang (No. 2020R52029), the National Natural Science Foundation of China and the Swedish Research Council Cooperative Research Project (No. 8211101233), the National Natural Science Foundation of China (No. 8217131437), and the Zhejiang Provincial Science and Technology Department’s “top soldier” and “leading wild goose” R & D project (No. 2022C03116).	

**Time frame: past 36 months**

2	Grants or contracts from any entity (if not indicated in item #1 above).	<input checked="" type="checkbox"/> None	
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	<input checked="" type="checkbox"/> None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None	
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	

8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

**Please summarize the above conflict of interest in the following box:**

This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of Zhejiang Province (No. 2018ZZ006, 2020ZZ003, 2021ZQ012, 2021ZA006, 2021ZQ012, and 2022ZZ001), the “10000 Talents Plan” of Zhejiang Province to Ping Huang (No. 2020R52029), the National Natural Science Foundation of China and the Swedish Research Council Cooperative Research Project (No. 8211101233), the National Natural Science Foundation of China (No. 8217131437), and the Zhejiang Provincial Science and Technology Department’s “top soldier” and “leading wild goose” R & D project (No. 2022C03116).

**Please place an “X” next to the following statement to indicate your agreement:**

X **I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

Date: March 18<sup>th</sup>, 2022  
 Your Name: Zongfu Pan  
 Manuscript Title: Heterogeneous microenvironment analysis to explore the potential regulatory role of endothelial-mesenchymal transition in idiopathic pulmonary fibrosis.  
 Manuscript number (if known): \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the **current manuscript only**.

The author’s relationships/activities/interests should be **defined broadly**. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<b>Funding:</b> This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of	

		Zhejiang Province (No. 2018ZZ006, 2020ZZ003, 2021ZQ012, 2021ZA006, 2021ZQ012, and 2022ZZ001), the “10000 Talents Plan” of Zhejiang Province to Ping Huang (No. 2020R52029), the National Natural Science Foundation of China and the Swedish Research Council Cooperative Research Project (No. 8211101233), the National Natural Science Foundation of China (No. 8217131437), and the Zhejiang Provincial Science and Technology Department’s “top soldier” and “leading wild goose” R & D project (No. 2022C03116).	

**Time frame: past 36 months**

2	Grants or contracts from any entity (if not indicated in item #1 above).	<input checked="" type="checkbox"/> None	
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	<input checked="" type="checkbox"/> None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None	
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	

8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

**Please summarize the above conflict of interest in the following box:**

This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of Zhejiang Province (No. 2018ZZ006, 2020ZZ003, 2021ZQ012, 2021ZA006, 2021ZQ012, and 2022ZZ001), the “10000 Talents Plan” of Zhejiang Province to Ping Huang (No. 2020R52029), the National Natural Science Foundation of China and the Swedish Research Council Cooperative Research Project (No. 8211101233), the National Natural Science Foundation of China (No. 8217131437), and the Zhejiang Provincial Science and Technology Department’s “top soldier” and “leading wild goose” R & D project (No. 2022C03116).

**Please place an “X” next to the following statement to indicate your agreement:**

X **I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

Date: March 18<sup>th</sup>, 2022  
 Your Name: Zhiyong Sun  
 Manuscript Title: Heterogeneous microenvironment analysis to explore the potential regulatory role of endothelial-mesenchymal transition in idiopathic pulmonary fibrosis.  
 Manuscript number (if known): \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the **current manuscript only**.

The author's relationships/activities/interests should be **defined broadly**. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<b>Funding:</b> This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of	

		Zhejiang Province (No. 2018ZZ006, 2020ZZ003, 2021ZQ012, 2021ZA006, 2021ZQ012, and 2022ZZ001), the “10000 Talents Plan” of Zhejiang Province to Ping Huang (No. 2020R52029), the National Natural Science Foundation of China and the Swedish Research Council Cooperative Research Project (No. 8211101233), the National Natural Science Foundation of China (No. 8217131437), and the Zhejiang Provincial Science and Technology Department’s “top soldier” and “leading wild goose” R & D project (No. 2022C03116).	

**Time frame: past 36 months**

2	Grants or contracts from any entity (if not indicated in item #1 above).	<input checked="" type="checkbox"/> None	
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	<input checked="" type="checkbox"/> None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None	
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	

8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

**Please summarize the above conflict of interest in the following box:**

This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of Zhejiang Province (No. 2018ZZ006, 2020ZZ003, 2021ZQ012, 2021ZA006, 2021ZQ012, and 2022ZZ001), the “10000 Talents Plan” of Zhejiang Province to Ping Huang (No. 2020R52029), the National Natural Science Foundation of China and the Swedish Research Council Cooperative Research Project (No. 8211101233), the National Natural Science Foundation of China (No. 8217131437), and the Zhejiang Provincial Science and Technology Department’s “top soldier” and “leading wild goose” R & D project (No. 2022C03116).

**Please place an “X” next to the following statement to indicate your agreement:**

X **I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

Date: March 18<sup>th</sup>, 2022  
 Your Name: Zhongjie Huang  
 Manuscript Title: Heterogeneous microenvironment analysis to explore the potential regulatory role of endothelial-mesenchymal transition in idiopathic pulmonary fibrosis.  
 Manuscript number (if known): \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the **current manuscript only**.

The author's relationships/activities/interests should be **defined broadly**. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<b>Funding:</b> This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of	

		Zhejiang Province (No. 2018ZZ006, 2020ZZ003, 2021ZQ012, 2021ZA006, 2021ZQ012, and 2022ZZ001), the “10000 Talents Plan” of Zhejiang Province to Ping Huang (No. 2020R52029), the National Natural Science Foundation of China and the Swedish Research Council Cooperative Research Project (No. 8211101233), the National Natural Science Foundation of China (No. 8217131437), and the Zhejiang Provincial Science and Technology Department’s “top soldier” and “leading wild goose” R & D project (No. 2022C03116).	

**Time frame: past 36 months**

2	Grants or contracts from any entity (if not indicated in item #1 above).	<input checked="" type="checkbox"/> None	
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	<input checked="" type="checkbox"/> None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None	
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	

8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

**Please summarize the above conflict of interest in the following box:**

This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of Zhejiang Province (No. 2018ZZ006, 2020ZZ003, 2021ZQ012, 2021ZA006, 2021ZQ012, and 2022ZZ001), the “10000 Talents Plan” of Zhejiang Province to Ping Huang (No. 2020R52029), the National Natural Science Foundation of China and the Swedish Research Council Cooperative Research Project (No. 8211101233), the National Natural Science Foundation of China (No. 8217131437), and the Zhejiang Provincial Science and Technology Department’s “top soldier” and “leading wild goose” R & D project (No. 2022C03116).

**Please place an “X” next to the following statement to indicate your agreement:**

X **I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

Date: March 18<sup>th</sup>, 2022  
 Your Name: Shuilian Zheng  
 Manuscript Title: Heterogeneous microenvironment analysis to explore the potential regulatory role of endothelial-mesenchymal transition in idiopathic pulmonary fibrosis.  
 Manuscript number (if known): \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<b>Funding:</b> This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of	

		Zhejiang Province (No. 2018ZZ006, 2020ZZ003, 2021ZQ012, 2021ZA006, 2021ZQ012, and 2022ZZ001), the “10000 Talents Plan” of Zhejiang Province to Ping Huang (No. 2020R52029), the National Natural Science Foundation of China and the Swedish Research Council Cooperative Research Project (No. 8211101233), the National Natural Science Foundation of China (No. 8217131437), and the Zhejiang Provincial Science and Technology Department’s “top soldier” and “leading wild goose” R & D project (No. 2022C03116).	

**Time frame: past 36 months**

2	Grants or contracts from any entity (if not indicated in item #1 above).	<input checked="" type="checkbox"/> None	
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	<input checked="" type="checkbox"/> None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None	
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	

8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

**Please summarize the above conflict of interest in the following box:**

This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of Zhejiang Province (No. 2018ZZ006, 2020ZZ003, 2021ZQ012, 2021ZA006, 2021ZQ012, and 2022ZZ001), the “10000 Talents Plan” of Zhejiang Province to Ping Huang (No. 2020R52029), the National Natural Science Foundation of China and the Swedish Research Council Cooperative Research Project (No. 8211101233), the National Natural Science Foundation of China (No. 8217131437), and the Zhejiang Provincial Science and Technology Department’s “top soldier” and “leading wild goose” R & D project (No. 2022C03116).

**Please place an “X” next to the following statement to indicate your agreement:**

X **I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

Date: March 18<sup>th</sup>, 2022  
 Your Name: Hansheng Pan  
 Manuscript Title: Heterogeneous microenvironment analysis to explore the potential regulatory role of endothelial-mesenchymal transition in idiopathic pulmonary fibrosis.  
 Manuscript number (if known): \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<u>Funding: This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of</u>	



8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

**Please summarize the above conflict of interest in the following box:**

This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of Zhejiang Province (No. 2018ZZ006, 2020ZZ003, 2021ZQ012, 2021ZA006, 2021ZQ012, and 2022ZZ001), the “10000 Talents Plan” of Zhejiang Province to Ping Huang (No. 2020R52029), the National Natural Science Foundation of China and the Swedish Research Council Cooperative Research Project (No. 8211101233), the National Natural Science Foundation of China (No. 8217131437), and the Zhejiang Provincial Science and Technology Department’s “top soldier” and “leading wild goose” R & D project (No. 2022C03116).

**Please place an “X” next to the following statement to indicate your agreement:**

X **I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

Date: March 18<sup>th</sup>, 2022  
 Your Name: Xiaozhou Zou  
 Manuscript Title: Heterogeneous microenvironment analysis to explore the potential regulatory role of endothelial-mesenchymal transition in idiopathic pulmonary fibrosis.  
 Manuscript number (if known): \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the **current manuscript only**.

The author’s relationships/activities/interests should be **defined broadly**. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<b>Funding:</b> This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of	



8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

**Please summarize the above conflict of interest in the following box:**

This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of Zhejiang Province (No. 2018ZZ006, 2020ZZ003, 2021ZQ012, 2021ZA006, 2021ZQ012, and 2022ZZ001), the “10000 Talents Plan” of Zhejiang Province to Ping Huang (No. 2020R52029), the National Natural Science Foundation of China and the Swedish Research Council Cooperative Research Project (No. 8211101233), the National Natural Science Foundation of China (No. 8217131437), and the Zhejiang Provincial Science and Technology Department’s “top soldier” and “leading wild goose” R & D project (No. 2022C03116).

**Please place an “X” next to the following statement to indicate your agreement:**

X **I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

Date: March 18<sup>th</sup>, 2022  
 Your Name: Ping Huang  
 Manuscript Title: Heterogeneous microenvironment analysis to explore the potential regulatory role of endothelial-mesenchymal transition in idiopathic pulmonary fibrosis.  
 Manuscript number (if known): \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the **current manuscript only**.

The author’s relationships/activities/interests should be **defined broadly**. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<b>Funding:</b> This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of	



8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

**Please summarize the above conflict of interest in the following box:**

This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of Zhejiang Province (No. 2018ZZ006, 2020ZZ003, 2021ZQ012, 2021ZA006, 2021ZQ012, and 2022ZZ001), the “10000 Talents Plan” of Zhejiang Province to Ping Huang (No. 2020R52029), the National Natural Science Foundation of China and the Swedish Research Council Cooperative Research Project (No. 8211101233), the National Natural Science Foundation of China (No. 8217131437), and the Zhejiang Provincial Science and Technology Department’s “top soldier” and “leading wild goose” R & D project (No. 2022C03116).

**Please place an “X” next to the following statement to indicate your agreement:**

X **I certify that I have answered every question and have not altered the wording of any of the questions on this form.**